Roche and Novartis face off in biosimilar drug battle

ZURICH, May 30 (Reuters) - Switzerland's biggest drugmakers

are clashing over cheaper copies of pricey biotech drugs - one

reason why Novartis is considering selling its $14

billion stake in cross-town rival Roche.

Read more